Zacks: Analysts Anticipate Phreesia, Inc. (NYSE:PHR) to Post -$1.09 Earnings Per Share

Equities research analysts expect Phreesia, Inc. (NYSE:PHRGet Rating) to post earnings of ($1.09) per share for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Phreesia’s earnings. The lowest EPS estimate is ($1.15) and the highest is ($1.03). Phreesia posted earnings of ($0.24) per share in the same quarter last year, which suggests a negative year over year growth rate of 354.2%. The firm is expected to announce its next earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Phreesia will report full-year earnings of ($4.07) per share for the current fiscal year, with EPS estimates ranging from ($4.67) to ($3.04). For the next financial year, analysts anticipate that the company will report earnings of ($3.74) per share, with EPS estimates ranging from ($4.54) to ($3.36). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Phreesia.

Phreesia (NYSE:PHRGet Rating) last announced its quarterly earnings data on Wednesday, March 30th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.03) by $0.33. The business had revenue of $58.02 million for the quarter, compared to the consensus estimate of $56.34 million. Phreesia had a negative net margin of 55.41% and a negative return on equity of 25.34%. Phreesia’s quarterly revenue was up 38.8% on a year-over-year basis. During the same quarter last year, the company posted ($0.18) earnings per share.

A number of research analysts have issued reports on PHR shares. Piper Sandler cut their price objective on Phreesia from $54.00 to $42.00 in a report on Monday, April 4th. SVB Leerink lowered their target price on Phreesia from $41.00 to $29.00 and set a “market perform” rating for the company in a research note on Thursday, March 31st. Citigroup lowered their target price on Phreesia from $54.00 to $36.00 and set a “neutral” rating for the company in a research note on Thursday, March 31st. Zacks Investment Research lowered Phreesia from a “buy” rating to a “hold” rating in a research note on Tuesday, April 5th. Finally, Guggenheim assumed coverage on Phreesia in a research note on Wednesday, April 13th. They issued a “buy” rating and a $45.00 target price for the company. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $50.00.

Hedge funds have recently made changes to their positions in the stock. IndexIQ Advisors LLC bought a new position in Phreesia in the first quarter valued at about $363,000. TimesSquare Capital Management LLC raised its position in Phreesia by 3.0% in the first quarter. TimesSquare Capital Management LLC now owns 846,790 shares of the company’s stock valued at $22,321,000 after purchasing an additional 24,985 shares during the last quarter. Aigen Investment Management LP bought a new position in Phreesia in the first quarter valued at about $265,000. Russell Investments Group Ltd. acquired a new stake in shares of Phreesia in the first quarter valued at about $197,000. Finally, Stephens Inc. AR increased its stake in shares of Phreesia by 51.3% in the first quarter. Stephens Inc. AR now owns 12,927 shares of the company’s stock valued at $341,000 after buying an additional 4,382 shares during the period. Institutional investors and hedge funds own 94.29% of the company’s stock.

Shares of PHR stock opened at $19.17 on Friday. The stock has a market cap of $982.27 million, a P/E ratio of -8.23 and a beta of 1.36. Phreesia has a one year low of $18.11 and a one year high of $76.10. The stock has a fifty day moving average price of $27.11 and a 200 day moving average price of $39.76. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.65 and a quick ratio of 5.65.

Phreesia Company Profile (Get Rating)

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments.

Read More

Get a free copy of the Zacks research report on Phreesia (PHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Phreesia (NYSE:PHR)

Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.